Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar;3(1):149-55.
doi: 10.2147/tcrm.2007.3.1.149.

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

R Lozano, Mg Peralta Concha, A Montealegre, L de Leon, J Ortiz Villalba, Ho Lee Esteban, M Cromeyer, Ja Rivas García, A Brossa, G Lluberes, E Izquierdo Sandí, H Burgos Quirós

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

R Lozano et al. Ther Clin Risk Manag. 2007 Mar.

Abstract

The objective of this study was to assess the effectiveness and safety of levosulpiride in patients with dysmotility-like functional dyspepsia including nonerosive reflux esophagitis in conditions of daily practice. The study was conducted as a prospective, open-label, multicenter design in 342 patients with dysmotility-like functional dyspepsia (n=279) and nonerosive reflux disease (n=63), who received levosulpiride 25 mg 3 times daily orally for 4 weeks. Individual symptoms (pain/discomfort, fullness, bloating, early satiety, pyrosis, regurgitation, and nausea/vomiting) and a global symptom score were assessed at 15, 30, and 60 days after starting treatment. Adverse events also were recorded. There were 151 men and 191 women (mean age 38.8 years) who referred dyspeptic symptoms for a mean of 10.2 (10.7) months. A total of 66.4% patients were treated with 75 mg/day levosulpiride and 33.6% with 50 mg/day. At the 15-day visit, a decrease greater than 50% in the global symptom score was observed. The frequency and intensity of individual symptoms showed a statistically significant decrease (p<0.001) at all visits compared with baseline. At the 30-day visit, all symptoms had almost disappeared, a trend that was maintained until the last visit. Treatment with levosulpiride was well tolerated and only 40 adverse events were recorded (galactorrhea 26.7%, somnolence 17.8%, fatigue 11.1%, headache 11.5%) and no patient had to abandon the study due to side effects. In conclusion, levosulpiride is an effective and safe drug in the treatment of dysmotility-like functional dyspepsia and non-erosive reflux disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Decrease of total symptom score during the study.
Figure 2
Figure 2
Changes in the severity of nausea throughout the study.
Figure 3
Figure 3
Changes in the severity of pyrosis throughout the study.
Figure 4
Figure 4
Changes in the severity of regurgitation throughout the study.
Figure 5
Figure 5
Changes in the severity of abdominal fullness throughout the study.
Figure 6
Figure 6
Intensity of adverse events at the follow-up visits.
See this image and copyright information in PMC

References

    1. Andresen V, Camilleri M. Challenges in drug development for functional gastrointestinal disorders. Part I: functional dyspepsia. Neurogastroenterol Motil. 2006;18:346–53. - PubMed
    1. Arienti V, Corazza GR, Sorge M, et al. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther. 1994;8:631–8. - PubMed
    1. Bodger K, Eastwood PG, Manning SI, et al. Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996) Aliment Pharmacol Ther. 2000;14:413–20. - PubMed
    1. Bytzer P. Diagnostic approach to dyspepsia. Best Pract Res Clin Gastroenterol. 2004;18:681–93. - PubMed
    1. Caballero Plasencia AM, Sofos Kontoyannis S, Valenzuela Barranco M, et al. Epidemiology of dyspepsia in a random Mediterranean population. Prevalence of Helicobacter pylori infection. Rev Esp Enferm Dig. 2000;92:781–92. - PubMed

LinkOut - more resources